The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.
Market capitalization (31-Oct-2017)
Closing share price (31-Oct-2017)